Profusa Reports $35.8 Million Net Loss and No Revenue for Fiscal Year 2025

Profusa, Inc., a digital health technology company based in Berkeley, California, reported significant financial challenges in its recent 10-K filing for the fiscal year ending December 31, 2025. The company incurred a net loss of $35.8 million, a substantial increase from the $9.2 million loss reported in the previous year. This increase in losses was primarily attributed to heightened operational costs associated with the company's transition to a public entity following its merger with Northview Acquisition Corporation in July 2025. Operating expenses surged to $27.7 million, up from $4.6 million in 2024, driven largely by a $14.5 million increase in transaction closing costs and a $4.3 million rise in personnel expenses.

In terms of revenue, Profusa reported no sales for the year, a stark contrast to the $100,000 in grant revenue recognized in 2024. The absence of revenue was linked to the company's focus on completing the business combination and preparing for future product launches. Profusa's primary product, Lumee Oxygen, has received CE mark approval in Europe and is expected to launch in the U.S. in late 2026, pending FDA approval. The company is also developing Lumee Glucose, a continuous glucose monitoring system, with plans for a dual sales strategy targeting both hospitals and pharmacies.

Operationally, Profusa is in the process of expanding its market presence, particularly in Europe, where it has established relationships with key opinion leaders and is working on reimbursement strategies. The company has also engaged in discussions for potential partnerships in Asia, aiming to leverage its technology in broader markets. As of December 31, 2025, Profusa had cash reserves of $1.8 million, which it plans to utilize for ongoing research and development, as well as commercialization efforts.

Looking ahead, Profusa faces substantial challenges, including the need for additional funding to support its operations and product development. The company has indicated that it may seek to raise capital through equity offerings or debt financing, but uncertainties surrounding market conditions and investor interest could complicate these efforts. Furthermore, the company has raised concerns about its ability to continue as a going concern, given its history of losses and the need for significant investment to achieve its commercialization goals. The upcoming months will be critical for Profusa as it navigates regulatory approvals and seeks to establish a foothold in the competitive digital health market.